PARP16 deficiency rescued cardiac dysfunction and ameliorated TAC-induced cardiac hypertrophy and fibrosis as well as PE-induced cardiomyocyte hypertrophic responses. This evidence concerns the gene PARP16 and cardiac hypertrophy.